COMPOSITIONS AND METHODS FOR TREATING HEMOSTASIS DISORDERS ASSOCIATED WITH CLEC-2 SIGNAL TRANSDUCTION
    3.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING HEMOSTASIS DISORDERS ASSOCIATED WITH CLEC-2 SIGNAL TRANSDUCTION 审中-公开
    用于治疗与CLEC-2信号转导相关的HEMOSTASIS疾病的组合物和方法

    公开(公告)号:WO2006115295A1

    公开(公告)日:2006-11-02

    申请号:PCT/JP2006/309066

    申请日:2006-04-24

    摘要: The present invention provides a method for screening compounds to identify therapeutic candidates for treating hemostasis disorders, the method includes the steps of contacting a cell that expresses a CLEC-2 receptor with a test compound and a CLEC-2 receptor ligand, under conditions which, but for the presence of the test compound, permit binding of the CLEC-2 receptor to the CLEC-2 receptor ligand; and detecting if any increase or decrease in an indicator of CLEC-2 receptor activity is observed in comparison to a control; wherein an increase or decrease in the indicator in comparison to the control indicates that the test compound is a candidate for modulating hemostasis.

    摘要翻译: 本发明提供了筛选化合物以鉴定治疗止血障碍的治疗候选物的方法,所述方法包括以下步骤:使表达CLEC-2受体的细胞与测试化合物和CLEC-2受体配体接触, 但是对于测试化合物的存在,允许CLEC-2受体与CLEC-2受体配体的结合; 并检测与对照相比是否观察到CLEC-2受体活性指标的增加或减少; 其中与对照相比指标的增加或减少表明测试化合物是调节止血的候选物。

    PLATELET ACTIVATION RECEPTOR CLEC-2: COMPOSITIONS AND USES THEREOF
    5.
    发明申请
    PLATELET ACTIVATION RECEPTOR CLEC-2: COMPOSITIONS AND USES THEREOF 审中-公开
    PLATELET激活受体CLEC-2:其组合物及其用途

    公开(公告)号:WO2008134445A2

    公开(公告)日:2008-11-06

    申请号:PCT/US2008/061446

    申请日:2008-04-24

    摘要: Disclosed are compositions comprising the platelet activation receptor C-type Lectin- like Receptor 2 (CLEC-2), and compositions comprising anti-CLEC-2 antibodies or antibodies that inhibit the interaction of CLEC-2 with podoplanin. Also disclosed are and methods of treating subjects in need thereof, comprising administering to the subject an effective amount of the disclosed compositions. Disclosed are recombinant CLEC-2 polypeptides, nucleic acids, antibodies, and compositions comprising recombinant CLEC-2 polypeptides, nucleic acids and antibodies. CLEC-2, has been found to interact with podoplanin. Recombinant CLEC-2 inhibits platelet aggregation induced by podoplanin- expressing tumor cells or lymphatic endothelial cells. Thus, CLEC-2 is responsible for platelet aggregation induced by endogenously expressed podoplanin on cell surfaces. CLEC- 2 is therefore a physiological target protein of podoplanin and is involved in podoplanin- induced platelet aggregation, tumor metastasis, and other cellular responses related to podoplanin. Disclosed are methods of treating, for instance, platelet aggregation-related disorders by administering effective amounts of the disclosed compositions to subjects in need thereof.

    摘要翻译: 公开了包含血小板活化受体C型凝集素样受体2(CLEC-2)的组合物和包含抗CLEC-2抗体或抑制CLEC-2与podoplanin的相互作用的抗体的组合物。 还公开了治疗有此需要的受试者的方法和方法,其包括向受试者施用有效量的所公开的组合物。 公开了重组CLEC-2多肽,核酸,抗体和包含重组CLEC-2多肽,核酸和抗体的组合物。 已经发现CLEC-2与podoplanin相互作用。 重组CLEC-2抑制由表达表达平滑蛋白的肿瘤细胞或淋巴内皮细胞诱导的血小板聚集。 因此,CLEC-2负责细胞表面内源表达的podoplanin诱导的血小板聚集。 因此,CLEC-2是podoplanin的生理目标蛋白,并且涉及podoplanin诱导的血小板聚集,肿瘤转移以及与podoplanin相关的其他细胞反应。 公开了通过向有需要的受试者施用有效量的所公开的组合物来治疗例如血小板聚集相关疾病的方法。